Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 50

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 50
---
 cash provided by (used in) operating activities and financing activities for the periods indicated (in thousands):

Nine Months Ended September 30,20252024Net cash used in operating activities$(6,832)$(12,552)Net cash provided by investing activities— 6,354 Net cash provided by financing activities11,309 424 Net increase (decrease) in cash and cash equivalents$4,477 $(5,774)

Operating Activities

Our cash used in operating activities for the nine months ended September 30, 2025 was $6.8 million, comprising of (i) our net loss of $8.6 million, as adjusted for $1.6 million in non-cash expenses (primarily for non-cash stock based compensation of $1.6 million), and (ii) net changes in operating assets and liabilities of $0.2 million.  

Our cash used in operating activities for the nine months ended September 30, 2024 was $12.6 million, comprising of (i) our net loss of $13.1 million, as adjusted for $2.3 million in non-cash expenses (primarily for non-cash stock based compensation of $2.2 million), and (ii) net changes in operating assets and liabilities of $1.7 million.  

Investing Activities

There were no investing activities during the nine months ended September 30, 2025.

Our cash provided by investing activities during the nine months ended September 30, 2024 was $6.4 million and was due to the redemption of marketable debt securities of $9.4 million, partially offset by the purchase of marketable debt securities of $3.1 million.

Financing Activities

Our cash provided by financing activities during the nine months ended September 30, 2025 was $11.3 million, primarily comprising of (i) $1.9 million in net proceeds received from the issuance of common stock and warrants in the April 2025 Offering, (ii) $1.8 million in net proceeds received from the issuance of common stock in the June 2025 Offering, and (iii) $7.6 million in net proceeds received from the issuance of common stock under the ATM Sales Agreement.

Our cash provided by financing activities during the nine months ended September 30, 2024 related to proceeds received from the exercise of options and warrants.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements